Breast Cancer Awareness Month: Advancing Breast Cancer Research through Clinical Trials

October 16, 2026 - Research progress in breast cancer is saving lives, improving treatments, and offering hope to millions of people. Yet breast cancer remains a significant public health challenge, underscoring the continued need for research, earlier detection, and more effective treatment options.

Breast cancer is the most common cancer in American women, after skin cancers, accounting for

• Read more

Alliance Announces FDA Approval of Atezolizumab Based on Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer

October 9, 2026

Chicago, IL - The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq^®) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colo

• Read more

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with SignateraTM MRD-Guided CDK4/6 Inhibitor Therapy in ER-Positive/HER2-Negative Early-Stage Breast Cancer

Trial will utilize Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s oral SERD, with the objective

• Read more